The GLP-1 Revolution: How Weight Loss Drugs Are Reshaping the Pharmaceutical Industry

The weight loss industry has long been a lucrative market, encompassing diet plans, supplements, exercise programs and surgical interventions. However, the landscape is rapidly changing, now dominated by a new class of drugs: GLP-1 medicines. Medications like Ozempic, Wegovy, Mounjaro, and Zepbound generated an estimated €50-60 billion in sales last year, with projections reaching €100 billion annually by the early 2030s – a remarkable growth trajectory for a market that barely existed a few years ago.

The Rise of GLP-1 Agonists

Novo Nordisk’s Ozempic, initially authorized for type 2 diabetes treatment in 2018, pioneered this field. Recognizing its weight loss potential, Novo Nordisk gained approval for Wegovy in 2021, specifically designed for weight loss. This proved incredibly profitable for the company. Between 2017 and 2023, Novo Nordisk’s sales nearly tripled, rising from 111.7 billion Danish krone to 309 billion DKK, with net profits increasing from just over 38 billion DKK to more than 102.4 billion DKK. While not solely attributable to Ozempic and Wegovy, these drugs have been the primary driver of this growth.

Economic Impact Beyond Pharma

Novo Nordisk’s success has had a significant impact on its native Denmark. The company accounted for approximately 11% of Danish GDP growth and around a fifth of its employment growth in the past year, directly and through its supply chain. Increased corporation tax revenue, a surge in exports, and a robust equities market have all benefited from Novo Nordisk’s performance. This has sparked conversations in Denmark, mirroring concerns seen in Ireland, regarding over-reliance on a single large pharmaceutical firm. However, recent GDP growth forecasts were lowered, partially due to factors related to Novo Nordisk.

Challenges to Novo Nordisk’s Dominance

Despite the success of Ozempic and Wegovy, Novo Nordisk’s share price has fallen, decreasing by over 60% in the past year and nearly 40% in the past month. This isn’t due to declining demand for GLP-1 drugs, but rather the company’s inability to capitalize on that demand as effectively as before. Novo Nordisk warned of potential profit and sales declines of up to 13% this year, citing “unprecedented pricing pressure,” influenced by efforts to align US drug prices with those in Europe.

Competition from Eli Lilly’s Mounjaro, approved in mid-2022, has also eroded Novo Nordisk’s market share, particularly in the US among cash buyers. Clinical trial results for Novo Nordisk’s new drug, CagriSema, showed an average weight loss of 23% over 84 weeks, slightly less than the 25.5% achieved with Mounjaro, failing to establish a new standard in the field.

Eli Lilly’s Ascent and the Irish Connection

Eli Lilly has also experienced substantial growth. Prior to Mounjaro’s approval in 2021, Lilly reported revenues of $28 billion and net profits of $5.6 billion. By 2023, revenues had more than doubled to over $65 billion, with net profits quadrupling to $20.6 billion. Mounjaro and Zepbound accounted for over half of Lilly’s total sales in 2023, generating $23 billion and $13.5 billion respectively.

Notably, Eli Lilly manufactures the key ingredient for Mounjaro and Zepbound – tirzepatide – at its facility in Kinsale, Cork, Ireland. A new facility is also opening in Limerick to meet growing demand. The Irish Fiscal Advisory Council attributes the surge in Irish exports last year almost entirely to Lilly’s ingredient shipments to the US, boosting GDP and corporation tax revenue. Lilly is believed to be a significant contributor to Ireland’s corporation tax income.

The Future of GLP-1s: Innovation and Generics

Numerous pharmaceutical companies are developing GLP-1 variants, with some pursuing licensing deals, such as AstraZeneca’s potential €4 billion agreement with a Chinese pharma firm. The hope is that increased competition will lower prices, creating a tiered market based on efficacy. More effective drugs may be targeted towards those with greater weight loss needs, while less potent options could be offered at lower price points.

Innovations in delivery methods are also emerging. Novo Nordisk has received approval for a pill version of Wegovy in the US, expected to reach the European market later this year. While clinical trials showed slightly lower efficacy than the injectable form, the pill may appeal to patients who prefer not to use injections and is cheaper to produce. The simpler supply chain for pills – easier packing and no need for cold storage – contributes to lower costs.

The expiration of patents will eventually lead to the availability of generic versions of these drugs. Novo Nordisk’s patent for semaglutide has already expired in some countries, including China and Brazil, and Canada due to a missed maintenance fee. Generic Ozempic is expected to enter the Canadian market this year, while Europe faces a longer wait until 2031. Eli Lilly’s patent for tirzepatide extends to around 2036 but is subject to potential challenges. The anticipated arrival of generics is expected to lower the overall market value, as spending per user decreases.

Beyond Weight Loss: Expanding Applications

Drug companies are also exploring additional applications for GLP-1 drugs. Zepbound is already approved for treating sleep apnea, and preliminary evidence suggests potential benefits in slowing kidney disease, managing Alzheimer’s, reducing blood pressure, and addressing addiction.

The growth of the GLP-1 market may also impact other sectors, with evidence suggesting reduced food purchases among users, potentially affecting food and beverage brands and supermarkets. There is also hope for positive impacts on healthcare systems through reduced obesity-related health conditions.

Despite their growth, GLP-1 drugs remain relatively niche, particularly in Ireland. The full impact of reduced obesity levels may take decades to fully assess.